Cue Biopharma, Inc. Logo

Cue Biopharma, Inc.

Develops injectable biologics to selectively activate T cells for oncology & autoimmune disease.

CUE | US

Overview

Corporate Details

ISIN(s):
US22978P1066
LEI:
Country:
United States of America
Address:
40 GUEST STREET, 2135 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company that develops a novel class of injectable biologics to selectively engage and modulate disease-specific T cells. The company's proprietary Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform engineers therapeutics designed to mimic natural immune signals. This approach aims to selectively expand and activate specific immune cells directly within the patient's body, mobilizing the immune system to treat serious diseases. Cue Biopharma's pipeline focuses on developing precision immunotherapies for oncology and autoimmune and inflammatory diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cue Biopharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cue Biopharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cue Biopharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden
SPAGO
Spero Therapeutics, Inc. Logo
Develops novel treatments for multi-drug resistant bacterial infections and rare diseases.
United States of America
SPRO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland
SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden
SPRINT
SPRUCE BIOSCIENCES, INC. Logo
Developing first-in-class therapies for serious, underserved neurological conditions like MPS IIIB.
United States of America
SPRB
Spyre Therapeutics, Inc. Logo
Engineering advanced antibody therapies for IBD and other immune diseases.
United States of America
SYRE
STADA Arzneimittel AG Logo
A leading European manufacturer of generics, consumer healthcare, and specialty pharmaceuticals.
Germany
SAZ
Stayble Therapeutics AB Logo
Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.
Sweden
STABL
STCUBE Logo
Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.
South Korea
052020
STELLA PHARMA CORPORATION Logo
Develops boron drugs for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiation treatment.
Japan
4888

Talk to a Data Expert

Have a question? We'll get back to you promptly.